Kazia Therapeutics Ltd · NASDAQ:KZIA
Kazia Therapeutics — Proactive Investors presentations, Sydney and Melbourne, February 2019
21 slides from Kazia Therapeutics's conference presentation, Feb 18, 2019
Slide 1: Kazia Presentation to Proactive Investors (ASX release)
ASX RELEASE 18 February 2019 KAZIA PRESENTATION TO PROACTIVE INVESTORS Sydney, 18 February 2019 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to provide the presentation to be delivered to Proactive Investors today in Sydney a
Slide 2: A company developing innovative, high-impact drugs for cancer
A company developing innovative, high-impact drugs for cancer Presentation to Proactive Investors Sydney, NSW & Melbourne, VIC 18 & 19 February 2019 ASX: KZA | NASDAQ : KZIA | Twitter: @KaziaTx
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the “safe- harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual
Slide 4: Reasons to invest in Kazia
Reasons to invest in Kazia We target a highly aggressive form of brain cancer, glioblastoma (GBM), in 1 which the only existing therapy provides no benefit to two-thirds of patients, and which represents a potential $1.5 billion commercial market Our lead program, GDC-0084, was designed by Genentech
Slide 5: Glioblastoma is the most common and most aggressive form of primary brain cancer
Glioblastoma (GBM) is the most common and most aggressive form of primary brain cancer Lung No clear 3-4 months 12-15 cause untreated months Breast or strong risk survival average 14 million factors survival with cancer cases treatment per annum Colon Any age, Five-year Prostate but most survival co
Slide 6: Treatment of GBM has improved little in recent decades, unlike other cancers
Treatment of GBM has improved little in recent decades, unlike other cancers Glio- 1990s 2000s 2010s blastoma Lung 1990s 2000s 2010s Cancer 4
Slide 7: Current treatment is essentially ineffective in approximately 65% of GBM cases
Current treatment is essentially ineffective in approximately 65% of GBM cases ~35% of patients respond to temozolomide Extends overall survival from Temozolomide is the only 15 to 22 months FDA-approved drug for newly-diagnosed patients ~65% of patients don’t respond to temozolomide Extends overall
Slide 8: GDC-0084 works by switching off a critical control mechanism
GDC-0084 works by switching off a critical control mechanism that drives many types of cancer PI3K ACTIVATED TUMOUR 85 – 90% of glioblastoma cases GROWTH have PI3K ‘switched on’ PI3K A central biochemical control mechanism in the PI3K INHIBITED growth of cells TUMOUR GDC-0084 switches off PI3K, INHI
Slide 9: GDC-0084 is the only drug of its kind able to cross the blood-brain barrier
GDC-0084 is the only drug of its kind that is able to cross the ‘blood-brain barrier’ (BBB) Most drugs cannot reach disease in the brain GDC-0084 crosses the BBB The ‘blood-brain barrier’ prevents most drugs from GDC-0084 was specifically designed for brain cancer, and getting into the brain, render
Slide 10: Phase 1 trial of GDC-0084 showed favourable safety and multiple efficacy signals
A phase 1 human trial of GDC-0084 showed favourable safety and multiple efficacy signals Safety Efficacy Signals • Phase I safety trial conducted by GDC-0084 Comparison Genentech 40% 21-52% • 47 patients enrolled with advanced glioma (grade 3/4); average of Arresting Achieved in studies of three pri
Slide 11: In the phase 1 trial, 7/27 patients (26%) showed a response
In the GDC-0084 phase 1 trial, 7 / 27 patients (26%) showed a response to drug* Pre-Dosing On GDC-0084 Pre-Dosing On GDC-0084 * Metabolic partial response per FDG-PET Analysis courtesy of Professor Ben Ellingson, UCLA Brain Tumor Imaging Laboratory 9
Slide 12: Kazia has started a phase 2 study and will report several data read-outs this year
Kazia has started a phase 2 study, and will report several data read-outs this year ✓ ✓ ✓ GDC-0084 Commence Commence Data read-out Data read-out Receipt of Start of phase potential other from phase 2a from phase 2a Orphan Drug 2a study in collaborations potential study (safety study Designation Glio
Slide 13: Leading researchers are testing the drug in other forms of brain cancer
Aside from Kazia’s GBM study, leading researchers are testing the drug in other forms of brain cancer Preclinical Phase I Phase II Phase III Glioblastoma Multiforme (GBM) (Kazia-sponsored) GDC-0084 Breast Cancer Brain Metastases (BCBM) PI3K / mTOR (collaboration with Dana- Inhibitor Farber Cancer In
Slide 14: Additional uses have the potential to significantly increase the commercial opportunity
INDICATIVE These additional uses of the drug have the potential to significantly increase the commercial opportunity Other potential future indications Glioblastoma HER2+ (most common Breast Cancer brain cancer) (Brain Metastases) ~$1.5B+ ~$3B+ market opportunity market opportunity 12
Slide 15: Cantrixil is in a phase 1 study in ovarian cancer, with data this year
A second program, Cantrixil, is currently in a phase 1 study in ovarian cancer, with data reporting this year Part A: Dose Escalation ✓ Part B: Dose Expansion • 3 to 42 patients in up to 8 • 12 patients, all at 5 mg/kg cohorts • Seeks to provide potential • Seeks to establish maximum efficacy signal
Slide 16: Kazia is now well-funded to see its R&D programs through key data read-outs
Kazia is now well-funded to see its R&D programs through key data read-outs in calendar 2019 Current funding allows:- $9.3M ~$2.5M* $4.2M • Completion of phase IIa GDC-0084 trial Current assets as at Shares in Noxopharm Proceeds from inst. 30 June 2018 (ASX:NOX) placement & SPP in Oct 18 • Completio
Slide 17: Kazia is NASDAQ & ASX listed
Kazia is NASDAQ & ASX listed Share Price (AU$) KZA 0.60 Current Assets (Jun 18) Debt US$ 6.9 million Nil 0.50 Market Capitalisation AU$ 26 million NASDAQ: KZIA (1:10 ratio) Listing ASX: KZA 0.40 NASDAQ: 0.4% /day Average Daily Volume ASX: 0.1% /day NASDAQ: US$ 100K /day Average Daily Value ASX: AU$
Slide 18: A strong team brings international experience in big pharma and early-stage biotech
A strong team brings international experience in big pharma and early-stage biotech Board Scientific Advisory Board Iain Ross Professor Sir Murray Brennan Chairman Emeritus Chairman of Cancer Surgery at Memorial Sloan Kettering Executive and Board roles in pharma Hospital, New York and small biotech
Slide 19: Other companies focused on the PI3K pathway have been highly-valued in the market
Other companies focused on the PI3K pathway have been highly-valued in the market Single asset company with one PI3K US$ 140 million inhibitor in phase I human trials Market Cap One PI3K inhibitor in phase II human US$ 430 million trials, one other drug in phase III, and two in animal testing Market
Slide 20: Reasons to invest in Kazia
Reasons to invest in Kazia We target a highly aggressive form of brain cancer, glioblastoma (GBM), in 1 which the only existing therapy provides no benefit to two-thirds of patients, and which represents a potential $1.5 billion commercial market Our lead program, GDC-0084, was designed by Genentech
Slide 21: www.kaziatherapeutics.com
www.kaziatherapeutics.com
Kazia Therapeutics — Proactive Investors presentations, Sydney and Melbourne, February 2019 on 6ix